To View the Online Program Planner, Go To
To view the online program planner, go to:
and then click on this link: View, Browse, Search Program Details (Online Program Planner)
(Please note that there are 4 additional Late-Breaking Clinical Science sessions)
LBCT.01.Late-Breaking Clinical Trials I.
Sunday, Nov 15, 2009, 3:45 PM - 5:13 PM
West Hall D2
Moderators:
Eric R Bates, Ann Arbor, MI
Jeffrey Weitz, Hamilton, ON, Canada
Presentations:
Sunday, Nov 15, 2009, 3:45 PM - 3:55 PM
91. First prospective comparison between platelet function tests in prediction clinical outcome in 1100 patients undergoing coronary stent placement Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in clopidogrel pretreated patients undergoing elective PCI (POPULAR study)
Nicoline J Breet, Heleen J Bouman, Jochem W van Werkum, Henk Ruven, Christian M Hackeng, Jurriën M ten Berg, St.Antonius Hosp, Nieuwegein, Netherlands
Sunday, Nov 15, 2009, 3:55 PM - 3:58 PM
92. Discussant
Franz J Neumann, Bad Krozingen, Germany
Sunday, Nov 15, 2009, 4:07 PM - 4:17 PM
93. The Results of the CHAMPION PCI Trial
Robert A. Harrington, on Behalf of the CHAMPION Executive Committee ., Duke Clinical Res Inst, Durham, NC
Sunday, Nov 15, 2009, 4:17 PM - 4:20 PM
94. Discussant
Alan Michelson, Boston, MA
Sunday, Nov 15, 2009, 4:29 PM - 4:39 PM
95. The Results of the CHAMPION PLATFORM Trial
Deepak L. Bhatt, On Behalf of the CHAMPION Executive Committee ., VA BOSTON HEALTHCARE SYSTEM AND BRIGHAM AND WOMEN'S HOSPITAL, Boston, MA
Sunday, Nov 15, 2009, 4:39 PM - 4:42 PM
96. Discussant
David P Faxon, Boston, MA
Sunday, Nov 15, 2009, 4:51 PM - 5:01 PM
97. Comparison of Ticagrelor, the First Reversible Oral P2Y12 Receptor Antagonist, with Clopidogrel in Patients with ST-Elevation Acute Coronary Syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Trial.
P Gabriel Steg, INSERM U-698, AP-HP and Univ Paris 7, Paris, France; Richard C Becker, Duke Clinical Res Inst, Durham, NC; Christopher P Cannon, TIMI Study Group, Brigham and Women's Hosp, Boston, MA; Hakan Emanuelsson, AstraZeneca R&D, Molndal, Sweden; Robert A Harrington, Duke Clinical Res Inst, Durham, NC; Jay Horrow, AstraZeneca, Wilmington, DE; Steen Husted, Aarhus Univ Hosp, Aarhus, Denmark; Hugo Katus, Univsklinikum Heidelberg, Heidelberg, Germany; Robert F Storey, Univ of Sheffield, Sheffield, United Kingdom; Lars C Wallentin, Uppsala Clinical Res Ctr, Uppsala, Sweden
Sunday, Nov 15, 2009, 5:01 PM - 5:04 PM
98. Discussant
Lisa K Jennings, Memphis, TN
Late-Breaking Clinical Trials II.
Monday, Nov 16, 2009, 10:45 AM -12:13 PM
West Hall D2
Moderators:
Jennifer H Mieres, New York, NY
John D Rutherford, Dallas, TX
Presentations:
Monday, Nov 16, 2009, 10:45 AM -10:55 AM
111. Outcomes Following Primary Percutaneous Coronary Intervention: A Comparison Between Hospitals With and Without Cardiac Surgery On-Site
Ather Anis, Boston Medical Ctr-Boston Univ, Boston, MA; Sharon-Lise T. Normand, Robert E. Wolf, Ann Lovett, Dept of Health Care Policy, Harvard Sch of Public Health, Boston, MA; Laura Mauri, Harvard Medical Sch, Brigham and Women’s Hosp, Boston, MA; Neal Patel, Alice K. Jacobs, Boston Medical Ctr-Boston Univ, Boston, MA
Monday, Nov 16, 2009, 11:07 AM -11:17 AM
112. ARBITER 6-HALTS: The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness
Allen J Taylor, Washington Hosp Ctr, Medstar Res Inst, Washington, DC; Todd C Villines, Patrick J Devine, Walter Reed Army Medical Ctr, Washington, DC; Mark Turco, Washington Adventist Hosp, Takoma Park, MD; Len Griffen, Cardiac Associates, Rockville, MD; Michael Miller, Univ of Maryland, Baltimore, MD; Eric J Stanek, None, Thorofare, NJ; Neil J Weissman, Washington Hosp Ctr, Medstar Res Inst, Washington, DC
Monday, Nov 16, 2009, 11:17 AM -11:20 AM
113. Discussant
John J Kastelein, Amsterdam, Netherlands
Monday, Nov 16, 2009, 11:29 AM -11:39 AM
114. Trial to Reduce Cardiovascular Events With Aranesp Therapy
Marc A Pfeffer, Brigham & Women's Hosp, Boston, MA; Emmanuel A. Burdmann, Faculdade de Medicina de Sao Jose, Sao Paulo, Brazil; Chao-Yin Chen, Amgen, Inc., Thousand Oaks, CA; Mark E. Cooper, Baker Heart Res Inst, Melbourne, VIC, Australia; Dick de Zeeuw, Univ Medical Ctr Groningen, Groningen, Netherlands; Kai-Uwe Eckardt, Univ of Erlangen-Nuremberg, Erlangen, Germany; Jan M. Feyzi, Univ of Wisconsin, Madison, WI; Peter Ivanovich, Northwestern Univ Feinberg, Chicago, IL; Reshma Kewalramani, Amgen, Inc., Thousand Oaks, CA; Andrew S. Levey, Tufts Medical Ctr, Boston, MA; Eldrin F. Lewis, Brigham & Women's Hosp, Boston, MA; Janet McGill, Washington Univ Medical Ctr, St. Louis, MO; John J.V. McMurray, Univ of Glasgow, Scotland, United Kingdom; Patrick Parfrey, Health Sciences Ctr, St. John's, NL, Canada; Hans-Henrik Parving, Univ of Copenhagen, Gentofte, Denmark; Giuseppe Remuzzi, Mario Negri Inst for Pharmacological Res, Bergamo, Italy; Ajay K. Singh, Scott D. Solomon, Brigham & Women's Hosp, Boston, MA; Robert Toto, Univ of Texas, Dallas, TX
Monday, Nov 16, 2009, 11:39 AM -11:42 AM
115. Discussant
Mary Cushman, Colchester, VT
Monday, Nov 16, 2009, 11:51 AM -12:01 PM
116. Impact of Transfusion Triggers on Postoperative Myocardial Infarction or Death
Jeffrey L Carson, UMDNJ-Robert Wood Johnson Medical Sch, New Brunswick, NJ; Michael L Terrin, Univeristy of Maryland, Baltimore, MD; Bernard Chaitman, St. Louis Univ, Saint Louis, MO; Jay Magaziner, Univeristy of Maryland, Baltimore, MD; David Sanders, London Health Sciences Ctr, Victoria Campus, London, ON, Canada
Monday, Nov 16, 2009, 12:01 PM -12:04 PM
117. Discussant
Paul W Armstrong, Edmonton, AB, Canada
LBCT.03.Late-Breaking Clinical Trials III.
Monday, Nov 16, 2009, 5:30 PM - 6:55 PM
W Chapin Theater
Moderators:
John Spertus, Kansas City, MO
Timothy J Gardner, Newark, DE
Presentations:
Monday, Nov 16, 2009, 5:30 PM - 5:40 PM
128. Clopidogrel And Aspirin Versus Aspirin Alone After Coronary Bypass Surgery: Results From The Clopidogrel After Surgery For Coronary Artery Disease (CASCADE) Randomized Controlled Trial
Alexander Kulik, Univ of Ottawa Heart Inst, Ottawa, ON, Canada; Pierre Voisine, Hop Laval, Quebec City, QC, Canada; Jean-Claude Tardif, Montreal Heart Inst, Montreal, QC, Canada; Robert De Larocheliere, Hop Laval, Quebec City, QC, Canada; George A. Wells, Thierry G. Mesana, Michel Le May, Marc Ruel, Univ of Ottawa Heart Inst, Ottawa, ON, Canada
Monday, Nov 16, 2009, 5:40 PM - 5:43 PM
129. Discussant
John Ikonomidis, Charleston, SC
Monday, Nov 16, 2009, 5:52 PM - 6:02 PM
130. Long-term Neurocognitive Outcome After Off-pump Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention, The Octopus Study
Jakub Regieli, Anne-Mette C Sauër, Klaas Dieleman, Diederik van Dijk, Erik W.L. Jansen, Diederick E Grobbee, Diederick E Grobbee, Pieter S Stella, Peter P.Th de Jaegere, Pieter A Doevendans, Hendrik M Nathoe, UMC UTRECHT, Utrecht, Netherlands
Monday, Nov 16, 2009, 6:02 PM - 6:05 PM
131. Discussant
Robert C Robbins, Stanford, CA
Monday, Nov 16, 2009, 6:11 PM - 6:21 PM
132. Telephone-Delivered Collaborative Care For Treating Post-CABG Depression: 8-Month Outcomes From The Bypassing The Blues Trial
Bruce L Rollman, Bea Herbeck Belnap, Sati Mazumdar, Patricia R Houck, Peter J Counihan, Wishwa N Kapoor, Univ of Pittsburgh, Pittsburgh, PA; Herbert C Schulberg, Weill Cornell Medical Coll, White Plains, NY; Charles F Reynolds, Univ of Pittsburgh, Pittsburgh, PA
Monday, Nov 16, 2009, 6:21 PM - 6:24 PM
133. Discussant
Frank Sellke, providence, RI
Monday, Nov 16, 2009, 6:33 PM - 6:43 PM
134. Non-steroidal Anti-Inflammatory Treatment for Post- operative Pericardial Effusion: The POPE Study A multicenter, double-blind, randomized trial
Philippe Meurin, Jean Yves Tabet, Les Grands Prés, Villeneuve Saint Denis, France; Gabriel Thabut, Hop Bichat, Paris, France; pascal Cristofini, Hop Broussais, paris, France; Titi Farrokhi, Hop Bligny, Briis sous forges, France; Michel Fischbach, Ctr de Réadaptation Château Lemoine, Cenon, France; Bernard Pierre, IRIS, Marcy l'étoile, France; Ahmed Ben Driss, Nathalie Renaud, Les Grands Prés, Villeneuve Saint Denis, France; Marie Christine Iliou, Hop Broussais, Paris, France; Hélène Weber, Les Grands Prés, Villeneuve Saint Denis, France
Monday, Nov 16, 2009, 6:43 PM - 6:46 PM
135. Discussant
Elliott Antman, Boston, MA
LBCT.04.Late-Breaking Clinical Trials IV.
Tuesday, Nov 17, 2009, 10:45 AM -12:13 PM
West Hall D2
Moderators:
Milton Packer, Dallas, TX
John GF Cleland, Hull, United Kingdom
Presentations:
Tuesday, Nov 17, 2009, 10:45 AM -10:55 AM
148. Comparison of Low-Dose Versus High-Dose Losartan Treatment on Morbidity and Mortality in Angiotensin Converting Enzyme Inhibitor-Intolerant Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction: Results of the HEAAL Study
Marvin A. Konstam, Tufts Medical Ctr, Boston, MA; James D. Neaton, Univ of Minnesota, Sch of Public Health, Minneapolis, MN; Kenneth Dickstein, Stavanger Univ Hosp, Stavanger, Norway; Helmut Drexler, Medische Hochschule, Hannover, Germany; Michel Komajda, Univ Pierre et Marie Curie-Paris, Paris, France; Felipe A. Martinez, Córdoba Natl Univ, Cordoba, Argentina; Gunter A.J. Riegger, Univ Hosp Regensburg, Regensburg, Germany; Ronald D. Smith, Merck, Whitehouse Station, NJ; William Malbecq, MSD-Europe, Brussels, Belgium; Soneil Guptha, Merck, Whitehouse Station, NJ; Philip A. Poole-Wilson, Natl Heart & Lung Inst, Imperial Coll, London, United Kingdom
Tuesday,Nov 17, 2009, 10:55 AM -10:58 AM
149. Discussant
Karl Swedberg, Goteborg Se, Sweden
Tuesday, Nov 17, 2009, 10:58 AM -11:07 AM
Panel Discussion
Tuesday, Nov 17, 2009, 11:07 AM -11:17 AM
150. FerricCarboxymaltose Assessment In Patients With Iron Deficiency And Chronic Heart Failure With And Without Anemia (FAIR-HF): A Randomized, Double-blind, Placebo-controlled, International Multi-center Phase III Study
Stefan D Anker, Charité Berlin, Dept of Cardiology, Campus CVK, Berlin, Germany; Josep Comin Colet, Hosp del Mar (IMAS), Barcelona, Spain; Gerasimos Filippatos, Athens Univ Hosp Attikon, Athens, Greece; Ronnie Willenheimer, Heart Health Group and Lund Univ, Malmö, Sweden; Kenneth Dickstein, Stavanger Univ Hosp, Stavanger, Norway; Helmut Drexler, Medische Hochschule Hannover, Hannover, Germany; Thomas Lüscher, Univ Hosp Zurich, Zurich, Switzerland; Claudio Mori, Vifor Pharma, Glattbugg, Switzerland; Barbara von Eisenhart Rothe, Vifor Pharma, Glattbrugg, Switzerland; Stuart Pocock, London Sch of Hygiene & Tropical Med, London, United Kingdom; Philip Poole-Wilson, Natl Heart & Lung Inst, London, United Kingdom; Piotr Ponikowski, Medical Univ, Wroclaw, Poland
Tuesday, Nov 17, 2009, 11:17 AM -11:20 AM
151. Discussant
Eldrin Lewis, Boston, MA
Tuesday, Nov17, 2009, 11:29 AM -11:39 AM
152. Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure (J-CHF) Study
Masatsugu Hori, Osaka Medical Ctr for Cancer and Cardiovascular Diseases, Osaka, Japan; Hiroshi Okamoto, Hokkaido Medical Ctr, Sapporo, Japan; Tsutomu Yamazaki, Univ of Tokyo, Tokyo, Japan; Tsutomu Yoshikawa, Keio Univ, Tokyo, Japan; Hiroyuki Tsutsui, Hokkaido Univ, Sapporo, Japan; Junichi Azuma, Osaka Univ, Suita, Japan; Masunori Matsuzaki, Yamaguchi Univ, Ube, Japan; Tohru Izumi, Kitasato Univ, Sagamihara, Japan; Yasuo Ohashi, Univ of Tokyo, Tokyo, Japan; Akira Kitabatake, Hokkaido Univ, Sapporo, Japan
Tuesday, Nov 17, 2009, 11:39 AM -11:42 AM
153. Discussant
Marco Metra, Brescia, Italy
Tuesday, Nov 17,2009, 11:51 PM -12:01 PM
154. Outcomes of Patients with Advanced Heart Failure Treated with Either a Pulsatile or Continuous Flow Left Ventricular Assist Device: Results of the HeartMate II Destination Therapy Trial
Joseph G Rogers,Duke Univ Medical Ctr, Durham, NC; Mark S Slaughter, Advocate Christ Medical Ctr, Oak Lawn, IL; Carmelo A Milano, Duke Univ Medical Ctr, Durham, NC; Stuart D Russell, John V Conte, Johns Hopkins Hosp, Baltimore, MD; David Feldman, Benjamin Sun, Ohio State Univ Medical Ctr, Columbus, OH; Antone J Tatooles, Advocate Christ Medical Ctr, Oak Lawn, IL; Reynolds M Delgado, Texas Heart Inst, Houston, TX; James W Long, Steven C Horton, Intermountain Medical Ctr, Salt Lake City, UT; Thomas C Wozniak, Waqas Ghumann, Clarian Methodist Hosp, Indianapolis, IN; David J Farrar, Thoratec Corp, Pleasanton, CA; O Howard Frazier, Texas Heart Inst, Houston, TX